Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT07677267 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

A Study of Real-World Characteristics, Treatment Patterns, and Outcomes Among mCRPC Patients Previously Treated With an Androgen Receptor Pathway Inhibitor, Taxane-Based Chemotherapy, and Lutetium-177 Vipivotide Tetraxetan

StatusRecruiting
PhaseNot specified
Started
View on ClinicalTrials.gov ↗
Trial flagged as At Risk
Primary completion moved at least 6 months later Nov 30, 2026 → May 31, 2027
See other at-risk trials from Novartis

Record History

See every version on ClinicalTrials.gov ↗

  1. Primary and study completion pushed from Nov 30, 2026 to May 31, 2027
    • Secondary endpoints: details revised at 4 of 8 entries
    • Eligibility criteria expanded, about 5 words
  2. Recruitment opened
    • Study sites: 0 to 1
    v2
  3. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
Novartis
555 trials monitored
See 34 trials at risk
Prostate Cancer
2,546 trials monitored
See 172 trials at risk
The aim of this study is to assess treatment patterns, characteristics, and clinical outcomes among adults with metastatic castration-resistant prostate cancer (mCRPC) who have previously received ≥1 androgen receptor pathway inhibitor (ARPI), ≥1 taxane, and 177Lu-PSMA-617 in the United States (US) real-world clinical practice. This study will be conducted using data extracted from the PRECISION (PRostatE Cancer dISease observatION) data platform.
Trial Details
NCT Number NCT07677267
Lead Sponsor Novartis Pharmaceuticals
Conditions
(from sponsor)		 Prostatic Neoplasms, Castration-Resistant
Related terms Prostatic Neoplasms, Castration-Resistant
Enrollment 1,067 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov